XJPX
206A
, Last price
Name
PRISM BioLab Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
677m
+121.62%
Net income
-834m
L-20.56%
CFO
-1.47b
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-helix or β-turn peptides, which are essential for protein-protein interactions. Through its platform, PRISM aims to discover drugs for what were previously considered 'undruggable targets,' with a pipeline including candidates for cancer and fibrotic diseases.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||